

# Product datasheet for TL314100V

## CD22 Human shRNA Lentiviral Particle (Locus ID 933)

## **Product data:**

Product Type:	shRNA Lentiviral Particles
Product Name:	CD22 Human shRNA Lentiviral Particle (Locus ID 933)
Locus ID:	933
Synonyms:	SIGLEC-2; SIGLEC2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CD22 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM 001185099</u> , <u>NM 001185100</u> , <u>NM 001185101</u> , <u>NM 001278417</u> , <u>NM 001771</u> , <u>NM 001771.1</u> , <u>NM 001771.2</u> , <u>NM 001771.3</u> , <u>NM 001185101.1</u> , <u>NM 001185100.1</u> , <u>NM 001185099.1</u> , <u>NM 001278417.1</u> , <u>BC109306</u> , <u>BC109307</u> , <u>NM 001185099.2</u> , <u>NM 001185100.2</u> , <u>NM 001771.4</u> , <u>NM 001278417.2</u>
UniProt ID:	<u>P20273</u>
Summary:	Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. [UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **CD22** Human shRNA Lentiviral Particle (Locus ID 933) – TL314100V

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US